US Patent

US9388416 — Modified oligonucleotides for telomerase inhibition

Method of Use · Assigned to Geron Corp · Expires 2026-09-09 · 0y remaining

Vulnerability score 93/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds that inhibit human telomerase activity with high potency and superior cellular uptake.

USPTO Abstract

Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.

Drugs covered by this patent

imetelstat-sodium (IMETELSTAT SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3956`	—	imetelstat-sodium
`U-3956`	—	imetelstat-sodium

Patent Metadata

Patent number: US9388416
Jurisdiction: US
Classification: Method of Use
Expires: 2026-09-09
Drug substance claim: No
Drug product claim: No
Assignee: Geron Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.